Abstract

The importance of long noncoding RNAs (lncRNAs) in the oncogenicity of hepatocellular carcinoma (HCC) has been widely studied. However, the detailed functions of ZSCAN16 antisense RNA 1 (ZSCAN16-AS1) have seldom been explored in HCC until the present study. In the present study, experiments were performed to clarify whether ZSCAN16-AS1 is implicated in the oncogenesis and progression of HCC and to explore the possible underlying mechanisms. ZSCAN16-AS1 expression was analyzed using reverse transcription-quantitative PCR. The effects of ZSCAN16-AS1 on the biological behavior of HCC cells were demonstrated by functional experiments. The direct binding capacity of ZSCAN16-AS1 with microRNA-451a (miR-451a) was indicated by the luciferase reporter assay and RNA immunoprecipitation. The high expression of ZSCAN16-AS1 was confirmed in HCC by The Cancer Genome Atlas database and the cohort of the present study. Survival data revealed that patients with a high ZSCAN16-AS1 level had worse prognosis compared with those with a low ZSCAN16-AS1 level. Following ZSCAN16-AS1 knockdown, HCC cell proliferation, migration and invasion were curbed, whereas cell apoptosis was promoted in vitro. The absence of ZSCAN16-AS1 restricted tumor growth of HCC cells in vivo. Mechanistically, ZSCAN16-AS1 acted as a competing endogenous RNA by decoying miR-451a in HCC cells. Furthermore, activating transcription factor 2 (ATF2), a direct target of miR-451a, was under the regulation of ZSCAN16-AS1, which was exerted by sequestering miR-451a. In addition, miR-451a knockdown or ATF2 resumption reversed the proliferation suppression, apoptosis promotion and migration and invasion inhibition triggered by ZSCAN16-AS1 silencing. In conclusion, ZSCAN16-AS1, a pro-oncogenic lncRNA, aggravated the malignancy of HCC by controlling the miR-451a/ATF2 axis. An understanding of the competing endogenous RNA network of ZSCAN16-AS1/miR-451a/ATF2 in HCC might be instrumental in the development of attractive targets for molecular therapy.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.